Your complement system consists of a group of important proteins in your bloodstream. These proteins help your immune system fight off harmful invaders, such as bacteria, and other foreign substances.

A complement blood test checks for autoimmune diseases or other issues with your immune system. Your doctor might test you if you have a family history of certain conditions, such as rheumatoid ...

The complement system is an important part of the humoral immune defence in mammals that is formed by about 35 soluble and cell-surface proteins. Together these proteins enable the host to recognize ...

Lynch joked that their dynamic is a balance of opposites, explaining that they “complement each other” as a bit of yin and ...

The human complement system has a pivotal role in the recognition, opsonization and elimination of microbial intruders. This functionality is maintained by a well-balanced interaction network of serum ...

Complement component 3, often called C3, is an essential protein of the immune system. This protein plays a vital role in the body’s innate immune system, providing: the first line of defense against ...

Among people with sickle cell disease—an inherited blood disorder—acute chest syndrome (ACS) is the leading cause of death. The condition is the result of red blood cells becoming stiff, sticky, and ...

Age-related macular degeneration is the most common cause of blindness in Western populations. Susceptibility is influenced by age and by genetic and environmental factors. Complement activation is ...

Novo Nordisk is paying $240 million for global rights to a Phase 3-ready drug from Omeros that could rival immune disorder medications currently available from companies such as AstraZeneca, Novartis, ...

Immunotherapy is increasingly becoming standard therapy in cancer, with technology, such as checkpoint inhibitors and cell therapy, raising the efficacy bar in many forms of the disease. But the ...

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim results from a Phase 1/2a clinical study of ARO-CFB, the company’s investigational RNA ...